Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Generic Pharma

Impax Laboratories Inc

+ Add to Watchlist

ILR:GR

35.840 EUR 0.375 1.04%

As of 10:38:27 ET on 03/02/2015.

Snapshot for Impax Laboratories Inc (ILR)

Open: 35.432 Day's Range: 35.006 - 36.055 Volume: 200
Previous Close: 36.215 52wk Range: 16.581 - 36.666 1-Yr Rtn: +90.54%

Stock Chart for ILR

No chart data available.
  • ILR:GR 35.840
  • 1D
  • 1M
  • 1Y
36.215
Interactive ILR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ILR

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 26.9958
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 1.4860
Est. PEG Ratio 0.9969
Market Cap (M EUR) 2,556.47
Shares Outstanding (M) 71.33
30 Day Average Volume 34
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ILR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ILR

Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The Company specializes in the development of niche and controlled release generics, as well as the development of branded products.

George Frederick Wilkinson "Fred"President/CEOMichael J NestorPres:Impax Pharmaceuticals
Bryan M ReasonsSenior VP:Finance/CFOMark A SchlossbergSenior VP/Secy/General Counsel
More Company Profile & Key Executives for ILR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil